RDY’s Q2 Results in Detail Dr. Reddy’s reports revenues under three segments — Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Others.

Reddy’ s Laboratories Ltd. today announced its consolidated financial results for the quarter ended Sep 30, 2023. Commenting on the results, Co-Chairman& MD, G V Prasad said:" We delivered ...

Dr. Reddy's Labs is experiencing a detrimental effect on their Q2 results and profits due to the high tax rate. The decrease in volumes has specifically impacted sequential sales in the US ...

Dr. Reddy's achieved remarkable financial performance, driven by strong sales growth across multiple markets, innovation, and corporate practices. Read more here.

Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.

India's Dr Reddy's Laboratories reported a bigger-than-expected rise in second-quarter profit on Friday, boosted by strong U.S. sales of its generic version of popular cancer drug Revlimid.

Dr Reddy’s Laboratories Ltd (NYSE:RDY) Q2 2024 Earnings Conference Call October 27, 2023 10:00 AM ETCompany ParticipantsRicha Periwal - IRParag Agarwal - ...

Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter ended Sep 30, 2023.

Reddy’ s Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2024. The information mentioned in this release is based on ...